These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 24692493)
61. What have RNAi screens taught us about viral-host interactions? Cherry S Curr Opin Microbiol; 2009 Aug; 12(4):446-52. PubMed ID: 19576842 [TBL] [Abstract][Full Text] [Related]
62. Toward a systems-level analysis of infection biology: a new method for conducting genetic screens in human cells. Stanley SA; Hung DT Sci Transl Med; 2009 Dec; 1(11):11ps13. PubMed ID: 20371455 [TBL] [Abstract][Full Text] [Related]
63. Manipulating and enhancing the RNAi response. Joyce PI; Gallagher JM; Kuwabara PE J RNAi Gene Silencing; 2006 Jan; 2(1):118-25. PubMed ID: 19771213 [TBL] [Abstract][Full Text] [Related]
64. Alternative Splicing Regulation of Cancer-Related Pathways in Caenorhabditis elegans: An In Vivo Model System with a Powerful Reverse Genetics Toolbox. Barberán-Soler S; Ragle JM Int J Cell Biol; 2013; 2013():636050. PubMed ID: 24069034 [TBL] [Abstract][Full Text] [Related]
65. Variable Dose Analysis: A Novel High-throughput RNAi Screening Method for Sierzputowska K; Baxter CR; Housden BE Bio Protoc; 2018 Dec; 8(24):e3112. PubMed ID: 34532554 [TBL] [Abstract][Full Text] [Related]
66. High-throughput screening by RNA interference: control of two distinct types of variance. Stone DJ; Marine S; Majercak J; Ray WJ; Espeseth A; Simon A; Ferrer M Cell Cycle; 2007 Apr; 6(8):898-901. PubMed ID: 17438372 [TBL] [Abstract][Full Text] [Related]
70. High-throughput worms. NemaPharm, Inc. Wells WA Chem Biol; 1998 Jun; 5(6):R147-8. PubMed ID: 9653546 [No Abstract] [Full Text] [Related]
71. Using Multiple Phenotype Assays and Epistasis Testing to Enhance the Reliability of RNAi Screening and Identify Regulators of Muscle Protein Degradation. Lehmann S; Shephard F; Jacobson LA; Szewczyk NJ Genes (Basel); 2012; 3(4):686-701. PubMed ID: 23152949 [TBL] [Abstract][Full Text] [Related]
72. Development of Small Molecular Proteasome Inhibitors Using a Caenorhabditis elegans Screen. Nayak S; Fiaschi M; King D; Tabakin ER; Wood L; Hunt DA Int J Med Chem; 2014; 2014():237286. PubMed ID: 25436151 [TBL] [Abstract][Full Text] [Related]
73. ASO Author Reflections: The Pressing Need for Germline Genetic Testing. Plichta JK; Hughes KS Ann Surg Oncol; 2019 Dec; 26(Suppl 3):612-613. PubMed ID: 31098782 [No Abstract] [Full Text] [Related]
74. Realizing the promise of RNAi high throughput screening. Bakal C; Perrimon N Dev Cell; 2010 Apr; 18(4):506-7. PubMed ID: 20412765 [TBL] [Abstract][Full Text] [Related]
75. High-throughput screening of small interfering ribonucleic acid identifies important modulators in islet dysfunction and apoptosis. Nemoto M; Sasaki T J Diabetes Investig; 2015 Jul; 6(4):390-2. PubMed ID: 26221516 [No Abstract] [Full Text] [Related]
76. Analysis of apoptosis in Caenorhabditis elegans. Lant B; Derry WB Cold Spring Harb Protoc; 2014 May; 2014(5):. PubMed ID: 24786497 [TBL] [Abstract][Full Text] [Related]